Literature DB >> 28766136

Zoledronic acid and bone cellular respiration.

Mohammed T Alsamri1, Suleiman Al-Hammadi1, Barira Islam1, Abdul-Kader Souid2.   

Abstract

Phosphorescence O2 analyzer was used to measure calvarial bone cellular respiration (cellular mitochondrial O2 consumption) in Taylor Outbred mice in the presence and absence of zoledronic acid. This potent bisphosphonate inhibits osteoclast-mediated calcium resorption, and its effects on bone respiration have not been previously investigated. The change of O2 concentration with time was measured in closed vials containing phosphate-buffered saline (PBS), 5 mM glucose and 5-25 mg calvarial bone fragments, and it was complex for t = 0-30 h. Cyanide (specific inhibitor of cytochrome oxidase) halted O2 consumption, confirming the oxidation occurred in the respiratory chain. Initial rate of respiration was estimated from the zero-order plots d[O2]/dt for t = 0-4 h. For untreated specimens, the rate (mean ± SD) was 2.0 ± 1.2 µM O2 h-1 mg-1 (n = 6). This value was 7-10 times lower than that of other murine organs, but similar to that reported for rat and Guinea pig calvaria (averaging, 2.7 nmol O2 h-1 mg-1). The corresponding rate in the presence of 10-100 µM zoledronic acid was 2.7 ± 0.7 µM O2 h-1 mg-1 (n = 11), p = 0.216. The first-order plots ln ([O2] t  ÷ [O2] t=0) versus time for t = 0-30 h were also used to compare treated and untreated specimens. The rate (h-1 mg-1 103) for specimens incubated in PBS without glucose was 1.3 ± 0.6 (n = 3, p = 0.007), in PBS + glucose it was 10.7 ± 6.9 (n = 10), in PBS + glucose + 10 µM zoledronic acid it was 12.1 ± 6.7 (n = 10, p = 0.579), in PBS + glucose + 20 µM zoledronic acid it was 12.9 ± 3.3 (n = 9, p = 0.356), and in PBS + glucose + 100 µM zoledronic acid it was 13.7 ± 7.7 (n = 9, p = 0.447). Thus, exposure to high-doses of zoledronic acid over several hours imposed a statistically insignificant increase in calvarial bone cellular respiration.

Entities:  

Keywords:  Bisphosphonates; Cellular bioenergetics; Mitochondria; Oxygen consumption; Respiratory chain

Mesh:

Substances:

Year:  2017        PMID: 28766136     DOI: 10.1007/s00774-017-0850-7

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  14 in total

1.  Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes.

Authors:  James Hynes; Lisa D Marroquin; Vladimir I Ogurtsov; Katerina N Christiansen; Gregory J Stevens; Dmitri B Papkovsky; Yvonne Will
Journal:  Toxicol Sci       Date:  2006-04-25       Impact factor: 4.849

Review 2.  A clinical and molecular overview of the human osteopetroses.

Authors:  W Balemans; L Van Wesenbeeck; W Van Hul
Journal:  Calcif Tissue Int       Date:  2005-11-16       Impact factor: 4.333

3.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

4.  Effects of two novel bisphosphonates on bone cells in vitro.

Authors:  C E Evans; I P Braidman
Journal:  Bone Miner       Date:  1994-08

5.  Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.

Authors:  Jürg A Gasser; Peter Ingold; Andrea Venturiere; Victor Shen; Jonathan R Green
Journal:  J Bone Miner Res       Date:  2008-04       Impact factor: 6.741

6.  Effect of combined treatment with zoledronic acid and parathyroid hormone on mouse bone callus structure and composition.

Authors:  Michele Casanova; Janelle Herelle; Marcel Thomas; Rowan Softley; Aaron Schindeler; David Little; Philipp Schneider; Ralph Müller
Journal:  Bone       Date:  2016-08-16       Impact factor: 4.398

7.  Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Authors:  David M Reid; Jean-Pierre Devogelaer; Kenneth Saag; Christian Roux; Chak-Sing Lau; Jean-Yves Reginster; Philemon Papanastasiou; Alberto Ferreira; Florian Hartl; Taiwo Fashola; Peter Mesenbrink; Philip N Sambrook
Journal:  Lancet       Date:  2009-04-11       Impact factor: 79.321

8.  Giant osteoclast formation and long-term oral bisphosphonate therapy.

Authors:  Robert S Weinstein; Paula K Roberson; Stavros C Manolagas
Journal:  N Engl J Med       Date:  2009-01-01       Impact factor: 91.245

9.  Fracture risk and zoledronic acid therapy in men with osteoporosis.

Authors:  Steven Boonen; Jean-Yves Reginster; Jean-Marc Kaufman; Kurt Lippuner; Jose Zanchetta; Bente Langdahl; Rene Rizzoli; Stanley Lipschitz; Hans Peter Dimai; Richard Witvrouw; Erik Eriksen; Kim Brixen; Luis Russo; Frank Claessens; Philemon Papanastasiou; Oscar Antunez; Guoqin Su; Christina Bucci-Rechtweg; Josef Hruska; Elodie Incera; Dirk Vanderschueren; Eric Orwoll
Journal:  N Engl J Med       Date:  2012-11-01       Impact factor: 91.245

10.  Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.

Authors:  Fraser P Coxon; Keith Thompson; Anke J Roelofs; F Hal Ebetino; Michael J Rogers
Journal:  Bone       Date:  2008-01-26       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.